Author

A. Dunbar

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Organism:mouse· 3 Research Focus:cancer & tumor microenvironment· 2 Research Focus:cell type annotation· 2 Research Focus:differential expression· 2 Assay:ATAC-seq· 1 Assay:bulk RNA-seq· 1 Research Focus:chromatin & epigenetic regulation· 1

Frequent Co-Authors

R. L. Bowman· 3 shared R. L. Levine· 3 shared W. Xiao· 3 shared Y. Park· 3 shared A. Karzai· 2 shared A. Krishnan· 2 shared A. R. Martinez Benitez· 2 shared D. A. Landau· 2 shared

Activity by Year

2021-2022 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 43 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

R. L. Bowman

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Modeling clonal evolution and oncogenic dependency in vivo in the context of hematopoietic transformation

R. L. Bowman, A. Dunbar, T. Mishra, W. Xiao, M. R. Waarts, I. Fernandez Maestre, S. E. Eisman, L. Cai, S. F. Cai, P. Sanchez Vela, S. Mowla, A. R. Martinez Benitez, Y. Park, I. S. Csete, A. Krishnan, , R. L. Levine

This study models clonal evolution and oncogenic dependency in hematopoietic transformation using reversible mutagenesis and allelic frameworks.

bioRxiv · May 18, 2022 · PreprintCancer Biology

Jak2V617F Reversible Activation Shows an Essential Requirement for Jak2V617F in Myeloproliferative Neoplasms

A. Dunbar, R. L. Bowman, Y. Park, F. Izzo, R. M. Myers, A. Karzai, W. Jun Kim, I. Fernandez Maestre, M. R. Waarts, A. Nazir, W. Xiao, M. Brodsky, M. Farina, L. Cai, S. F. Cai, , R. L. Levine

This study shows that reversible activation of Jak2V617F in a mouse model demonstrates its essential role in myeloproliferative neoplasms and highlights the therapeutic potential of mutant-specific JAK2 inhibition.

bioRxiv · May 18, 2022 · PreprintCancer Biology

Integrated Single-Cell Genotyping and Chromatin Accessibility Charts JAK2V617F Human Hematopoietic Differentiation

R. M. Myers, F. Izzo, S. Kottapalli, T. Prieto, A. Dunbar, R. L. Bowman, E. P. Mimitou, M. Stahl, S. El Ghaity-Beckley, J. Arandela, R. Raviram, S. Ganesan, L. Mekerishvili, R. Hoffman, R. Chaligne, , D. A. Landau

This paper develops GoT-ChA to link genotypes to chromatin accessibility in single cells, revealing JAK2V617F mutation-induced epigenetic changes in hematopoietic differentiation.

bioRxiv · May 11, 2022 · PreprintCancer Biology

CXCL8/CXCR2 signaling mediates bone marrow fibrosis and represents a therapeutic target in myelofibrosis

A. Dunbar, D. Kim, M. Lu, M. Farina, J. L. Yang, Y. Park, F. Gobbo, P. Verachi, F. Martelli, A. Karzai, W. Xiao, L. Xia, N. Elmansy, M. Kleppe, Z. Chen, , R. Hoffman

This study identifies CXCL8/CXCR2 signaling as a driver of bone marrow fibrosis in myelofibrosis and shows its therapeutic potential through genetic and pharmacologic inhibition.

bioRxiv · Dec 8, 2021Cancer Biology